Johnson & Johnson has announced results from an open-label Phase 2 study evaluating adjuvant treatment with Erleada (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC (high-risk localized prostate cancer) who have undergone radical prostatectomy (RP).

After RP, patients who received the regimen had a biochemical recurrence-free rate (BCR) of 100% at 24 months.

The results of this study encourage further research into high-risk localized prostate cancer, and highlight the promise of introducing treatment at early stages of the disease after radical prostatectomy," commented Neal Shore, Chief Medical Officer of Surgical Oncology and Urology at Genesis Care.

Copyright (c) 2024 CercleFinance.com. All rights reserved.